FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arbuckle Stuart A</u>				2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	MUNOGEN	I, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022									Officer below)	(give title	e Other (s below)		pecify
830 WINTER STREET (Street) WALTHAM MA 02451				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
2. Transact Date (Month/Date) Table II - Derivati (e.g., pu 1. Title of 2. Derivative Conversion Date Date Execution Date Transaction Date Date					cation 2A. Deemed Execution Date, if any (Month/Day/Year) 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.			3. Transactic Code (Ins 8) Code V uired, Dis , options,	Transaction Code (Instr. 3, 2			Price Pficially rities)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) Ally Owned S) unt Derivative Security Security Security Security Security		Form (D) or (I) (In	: Direct Indirect Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4) 11. Nature of Indirect Beneficial	
(Instr. 3)				Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Expiration Exercisable Date		tion	Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		(Instr. 5)	Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Direct (D) or Indirect (I) (Instr. 4)				
Deferred Share Unit	\$0 ⁽¹⁾	06/15/2022			A		15,000		(2)(3)	(3)		Common Stock ⁽³⁾	15,000	\$0 ⁽¹⁾	63,00	0	D	
Stock Option (right to buy)	\$3.37	06/15/2022			A		44,000		(4)	06/15/2	2032	Common Stock	44,000	\$3.37	44,00	0	D	

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.
- 3. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- 4. Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.

/s/ Renee Lentini, Attorney-in-

06/17/2022

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.